Literature DB >> 28194695

Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS).

Craig Ian Coleman1, Matthias Antz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28194695     DOI： 10.1007/s11739-017-1624-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  4 in total

1.  Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.

Authors:  Craig I Coleman; Matthias Antz; Kevin Bowrin; Thomas Evers; Edgar P Simard; Hendrik Bonnemeier; Riccardo Cappato
Journal:  Curr Med Res Opin       Date:  2016-09-20       Impact factor: 2.580

2.  Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke.

Authors:  Mark J Alberts; W Frank Peacock; Larry E Fields; Thomas J Bunz; Elaine Nguyen; Dejan Milentijevic; Jeff R Schein; Craig I Coleman
Journal:  Int J Cardiol       Date:  2016-04-04       Impact factor: 4.164

3.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

4.  Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.

Authors:  Xiaoxi Yao; Neena S Abraham; Lindsey R Sangaralingham; M Fernanda Bellolio; Robert D McBane; Nilay D Shah; Peter A Noseworthy
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501
  4 in total
  5 in total

1.  The involvement of pharmacies in the screening of undiagnosed atrial fibrillation.

Authors:  Pietro Amedeo Modesti; Gianni Donigaglia; Plinio Fabiani; Nicola Mumoli; Andrea Colella; Maria Boddi
Journal:  Intern Emerg Med       Date:  2017-09-19       Impact factor: 3.397

2.  Clinical Discussions in Antithrombotic Therapy Management : A Delphi Consensus Panel.

Authors:  Gabriello Marchetti; Emanuele Bertaglia; Alberto Camerini; Giuseppe De Angelis; Lucia Filippucci; Antonio Maggi; Sebastiano Marra; Carlo Racani; Carlo Serrati
Journal:  J Atr Fibrillation       Date:  2020-02-28

3.  Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel.

Authors:  Nicola Mumoli; Claudia Amellone; Gianfranco Antonelli; Giuseppe Augello; Cosima Cloro; Alberto D'Alleva; Leonardo Di Ascenzo; Egidio Imbalzano; Renato Masala; Graziano Riccioni; Emanuele Romeo; Luca Rossi; Giosuè Santoro; Edoardo Sciatti; Antonio Tondo; Elisabetta Toso; Elio Venturini; Enrico Vizzardi; Giosuè Mascioli
Journal:  CJC Open       Date:  2020-07-23

4.  Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation.

Authors:  A Di Lenarda; D Gabrielli; F Trotta; L Gozzo; F Mammarella; P P Olimpieri; A Cirilli; M Cuomo; M M Gulizia; F Colivicchi; G Murri; S K Kunutsor
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

5.  Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users.

Authors:  Karin Hedenmalm; Alexandra Pacurariu; Jim Slattery; Xavier Kurz; Gianmario Candore; Rob Flynn
Journal:  Drug Saf       Date:  2021-07-17       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.